Diabetes Therapies Need Cardiovascular Safety Data For Approval, Panel Says
Executive Summary
Sponsors of new type 2 diabetes therapies should be required to provide clinical data that can exclude an unacceptable cardiovascular risk prior to approval, FDA's Endocrinologic and Metabolic Drugs Advisory Committee concluded at a July 1-2 meeting
You may also be interested in...
Type 2 Diabetes Developers Take Heart: New Safety Hurdle Is Surmountable
The April 1-2 meeting of the Endocrinologic & Metabolic Drugs Advisory Committee ended in equivocal results for the sponsors involved, but sends an unequivocal message of hope to diabetes drug development companies: the new cardiovascular safety bar adopted by FDA in December is surmountable
Type 2 Diabetes Developers Take Heart: New Safety Hurdle Is Surmountable
The April 1-2 meeting of the Endocrinologic & Metabolic Drugs Advisory Committee ended in equivocal results for the sponsors involved, but sends an unequivocal message of hope to diabetes drug development companies: the new cardiovascular safety bar adopted by FDA in December is surmountable
Bristol/AZ Saxagliptin Safety Review: All Signs Point to Positive Committee Outcome
Upcoming FDA advisory committee review of DPP4 inhibitor poses first test of new diabetes cardiovascular safety guidelines. Bristol and AstraZeneca won’t be the only companies watching carefully.